This interactive CME-certified Webcast contains video and downloadable slides from the dinner meeting Bringing Confidence to the Delivery of Chemotherapy Through Improvements in Antiemetics, a prIME Oncology educational activity that was held on 27 September 2015, in Vienna, Austria.
New developments in antiemetic management
Matti Aapro, MD
Anticipating chemotherapy-induced nausea and vomiting (CINV): Can I get my patient’s antiemetic management right the first time?
George Dranitsaris, BPharma, MS, PhD, FCSHP
Matti Aapro, MDMultidisciplinary Oncology Institute
George Dranitsaris, BPharma, MS, PhD, FCSHPThe Ottawa Hospital Cancer Centre
This educational activity is specifically designed for oncologists, hematologists, and other healthcare professionals interested in and/or involved in ensuring safe and tolerable delivery of cytotoxic therapy to patients with cancer.
After successful completion of this educational activity, participants should be able to:
- Describe the therapeutic options recommended by international guidelines to manage immediate, delayed, and anticipatory emesis in patients receiving chemotherapy in routine clinical practice
- Evaluate emerging clinical trial data regarding novel therapeutic approaches for CINV and the potential role of these new regimens in clinical practice
- Understand how to integrate risk factors when assessing individual patient risk for CINV
- Apply appropriate treatment strategies to individualize antiemetic therapy
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure of Relevant Financial Relationships
prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.
This activity is provided by prIME Oncology.
prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.
prIME Oncology designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This educational activity is supported by Helsinn Healthcare SA.
October 30, 2015
October 30, 2016